Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 3Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Thoracic 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 27Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × budigalimab × Thoracic × Clear all
NCT06158958 2025-10-27

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

AbbVie

Phase 1 Terminated
27 enrolled
GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡